Sugi Predict

Sugi Predict / Compounds / SCHEMBL21521446

SCHEMBL21521446

SCHEMBL21521446

COC(=O)CCOCCNC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.47
▸ GAA P10253 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CA12 O43570 6/20 0.43
▸ CA2 P00918 6/20 0.43
▸ CA1 P00915 5/20 0.43
▸ CA9 Q16790 5/20 0.43
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ IDO1 P14902 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ EPHX1 P07099 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ BCHE P06276 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ ADRB2 P07550 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699508 0.98 TDP1 (0.46) TDP1GAAMEN1KMT2ACA12
SCHEMBL22256341 0.98 TDP1 (0.46) TDP1GAAMEN1KMT2ACA12
SCHEMBL21082300 0.98 TDP1 (0.46) TDP1GAAMEN1KMT2ACA12
SCHEMBL25756409 0.98 TDP1 (0.46) TDP1GAAMEN1KMT2ACA12
SCHEMBL14742521 0.92 TDP1 (0.49) TDP1GAAMEN1KMT2ACA12
SCHEMBL24922459 0.90 TDP1 (0.40) TDP1GAAMEN1KMT2ACA12
SCHEMBL13399480 0.90 CA1 (0.47) TDP1GAAMEN1KMT2ACA12
SCHEMBL18886420 0.90 TDP1 (0.47) TDP1GAAMEN1KMT2ACA12
SCHEMBL19451348 0.90 TDP1 (0.47) TDP1GAAMEN1KMT2ACA12
SCHEMBL22940210 0.89 TDP1 (0.47) TDP1GAAMEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 — — US disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 — — EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 — — US disclosed
EP-3788040-B1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-04-12 — — EP disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 — — US disclosed
US-20220162262-A1 NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2022-05-26 — — US disclosed
US-20220072141-A1 PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2022-03-10 — — US disclosed
US-11014913-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2021-05-25 — — US disclosed
EP-3788040-A1 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2021-03-10 — — EP disclosed
CN-112424188-A Pyridazinones as PARP7 inhibitors 里邦医疗公司 2021-02-26 — — CN disclosed
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2021-01-28 — — US disclosed
US-10870641-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2020-12-22 — — US disclosed
WO-2020201743-A1 NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF CENTAURI THERAPEUTICS LIMITED (GB) 2020-10-08 — — WO disclosed
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2020-04-23 — — US disclosed
US-10550105-B2 Pyridazinones as PARP7 inhibitors Ribon Therapeutics Inc. (US) 2020-02-04 — — US disclosed
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2019-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885
US-10550105-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885
US-20220072141-A1 PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF TGM2, QPCT, TGM3 TDP1 426/4885GAA 107/4885MEN1 847/4885
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885
US-11014913-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885
US-10870641-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885
US-20220162262-A1 NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF MAVS, MYD88, CD47 TDP1 2941/4885GAA 423/4885MEN1 2217/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 TDP1 223/4885GAA 3492/4885MEN1 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.